Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2025
vol. 20
 
Share:
Send email
Share:
Original paper

Apoptosis markers in children with metabolic-associated fatty liver disease: a preliminary study

Katarzyna Zdanowicz
1
,
Anna Bobrus-Chociej
1
,
Marta Flisiak-Jackiewicz
1
,
Monika Kowalczuk-Kryston
1
,
Jacek Jamiolkowski
1
,
Wlodzimierz Mielech
1
,
Dariusz M. Lebensztejn
1

  1. Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology, Medical University of Bialystok, Bialystok, Poland
Gastroenterology Rev 2025; 20 (1): 41–47
DOI: https://doi.org/10.5114/pg.2025.148527
Online publish date: 2025/03/16
Article files
- Apoptosis markers.pdf  [0.11 MB]
- Apoptosis markers - supplementary tables.pdf  [0.04 MB]
Get citation
 
PlumX metrics:
 
1. The Lancet Diabetes Endocrinology. Childhood obesity: a growing pandemic. Lancet Diabetes Endocrinol 2022; 10: 1.
2. Zdanowicz K, Bobrus-Chociej A, Lebensztejn DM. Chemerin as potential biomarker in pediatric diseases: a PRISMA-compliant study. Biomedicines 2022; 10: 591.
3. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021; 6: 864-73.
4. Zhang X, Wu M, Liu Z, et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open 2021; 11: e042843.
5. Ramírez-Mejía MM, Díaz-Orozco LE, Barranco-Fragoso B, et al. A review of the increasing prevalence of metabolic-associated fatty liver disease (MAFLD) in children and adolescents worldwide and in mexico and the implications for public health. Med Sci Monit 2021; 27: e934134.
6. Liu J, Mu C, Li K, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. Int J Public Health 2021; 66: 1604371.
7. Xing Y, Fan J, Wang HJ, et al. Comparison of MAFLD and NAFLD characteristics in children. Children 2023; 10: 560.
8. Kumar S, Duan Q, Wu R, et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev 2021; 176: 113869.
9. Ku NO, Strnad P, Zhong BH,et al. Keratins let liver live: mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology 2007; 46: 1639-49.
10. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-6.
11. Akwii RG, Sajib MS, Zahra FT, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 2019; 8: 471.
12. Radmanić L, Zidovec-Lepej S. The role of stem cell factor, epidermal growth factor and angiopoietin-2 in HBV, HCV, HCC and NAFLD. Life 2022; 12: 2072.
13. Zhang H, Rios RS, Boursier J, et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. Chin Med J 2023; 136: 341-50.
14. Liebig S, Stoeckmann N, Geier A, et al. Multicenter validation study of a diagnostic algorithm to detect NASH and fibrosis in NAFLD patients with low NAFLD fibrosis score or liver stiffness. Clin Transl Gastroenterol 2019; 10: e00066.
15. Eguchi A, Iwasa M, Yamada M, et al. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. Hepatol Commun 2022; 6: 1987-99.
16. Tada T, Kumada T, Toyoda H, et al. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Biomarkers 2018; 23: 328-34.
17. Arab JP, Hernández-Rocha C, Morales C, et al. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Gastroenterol Hepatol 2017; 40: 388-94.
18. Kułaga Z, Litwin M, Tkaczyk M, et al. Polish 2010 growth references for school-aged children and adolescents. Eur J Pediatr 2011; 170: 599-609.
19. Xi B, Zong X, Kelishadi R, et al. International waist circumference percentile cutoffs for central obesity in children and adolescents aged 6 to 18 Years. J Clin Endocrinol Metab 2020; 105: e1569-83.
20. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13-5.
21. Kanda T, Matsuoka S, Yamazaki M, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol 2018; 24: 2661-72.
22. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018; 75: 3313-27.
23. Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE. Int J Mol Sci 2021; 22: 818.
24. Intke C, Korpelainen S, Lappalainen M, et al. Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia. Clin Exp Med 2022; 22: 83-93.
25. Yu EL, Schwimmer JB. Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2021; 17: 196-9.
26. Fitzpatrick E, Mitry RR, Quaglia A, et al. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 2010; 51: 500-6.
27. Lebensztejn DM, Wierzbicka A, Socha P, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol 2011; 58: 563-6.
28. Vuppalanchi R, Jain AK, Deppe R, et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2121-30.e1-2.
29. Manco M, Panera N, Crudele A, et al. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease. Pediatr Res 2022; 91: 1781-6.
30. Feldstein AE, Alkhouri N, De Vito R, et al. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013; 108: 1526-31.
31. Zdanowicz K, Olanski W, Kowalczuk-Kryston M, et al. Total keratin-18 (M65) as a potential, early, non-invasive biomarker of hepatocyte injury in alcohol intoxicated adolescents – a preliminary study. Biomolecules 2021; 11: 911.
32. Kobayashi N, Kumada T, Toyoda H, et al. Ability of cytokeratin-18 fragments and FIB-4 Index to diagnose overall and mild fibrosis nonalcoholic steatohepatitis in Japanese nonalcoholic fatty liver disease patients. Dig Dis 2017; 35: 521-30.
33. Chuah KH, Wan Yusoff WNI, Sthaneshwar P, et al. MACK-3 (combination of hoMa, Ast and CK18): a promising novel biomarker for fibrotic non-alcoholic steatohepatitis. Liver Int 2019; 39: 1315-24.
34. Brown E, Hydes T, Hamid A, et al. Emerging and established therapeutic approaches for nonalcoholic fatty liver disease. Clin Ther 2021; 43: 1476-504.
35. Lefere S, Van de Velde F, Hoorens A, et al. Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease. Hepatology 2019; 69: 1087-104.
36. Wolfs MG, Gruben N, Rensen SS, et al. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr Diabetes 2015; 5: e146.
37. Dezsőfi A, Baumann U, Dhawan A, et al. Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2015; 60: 408-20.
38. Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol 2020; 73: 1322-32.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.